$heff's $tation of $tocks & $olid DD

[$heff]

$ALNY..Alnylam price target raised to $180 from $155 at Piper Jaffray.

Piper Jaffray analyst Edward Tenthoff raised his price target for shares of Alnylam Pharmaceuticals to $180 after the company reported preliminary Phase I ALN-CC5 data at the European Hematology Association meeting. Hemolysis was lowered by an average of 43% with a max knockdown of 61% after a single dose, making ALN-CC5 the company's fourth RNAi drug to achieve human proof-of-concept, Tenthoff pointed out. He views Alnylam as an emerging orphan drug play with multiple potential blockbusters and reiterates an Overweight rating on the name. The stock closed Friday down $2.46 to $130.28.